February 10, 2021 The worldwide lupus community lost a brilliant researcher and a passionate champion with the recent passing of rheumatologist Marc Chevrier, MD, PhD, FACR. A larger-than-life personality with a huge heart to match, Dr. Chevrier was a devoted friend to hundreds of people with lupus and those who care for them. Perhaps most […] READ MORE
February 4, 2021 “Imagine that your house is on fire and someone inside started it – that’s lupus,” says Dr. Giya Harry. “Steroids are the fire hoses we’re using to put the fire out fast! Other medications are the tools to rebuild the house and protect it from catching fire again.” Using concrete comparisons like […] READ MORE
January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […] READ MORE
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] READ MORE
January 14, 2020 Dear Friends, Happy New Year! On behalf of all of us at the Lupus Research Alliance (LRA), thank you so much for your kindness and generosity in 2020 and prior years. 2021 starts off with some exciting milestones for the lupus community including a new treatment for lupus nephritis. But Recently, our […] READ MORE
January 14, 2021 LRA’s President and CEO Kenneth Farber taped this video series – Vaccines and Lupus: What to Know Amid COVID-19 – to explain what vaccines do, how the new COVID-19 vaccine technologies work, and what the LRA is doing to address questions on the safety of these new vaccines for people with lupus. […] READ MORE
December 28, 2020 After much back and forth, last week the U.S. Congress passed the year-end spending deal, called the Omnibus, and President Trump signed it into law Sunday night. It’s because of your efforts during the LRA’s Virtual Hill Day in March that the need to fund research for lupus and other medical conditions […] READ MORE
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] READ MORE
Updated January 4, 2021 New York, NY– December 16, 2020. More than half of people with lupus (54%) are willing to take a COVID-19 vaccine if it is free and determined safe by scientists according to results of a survey conducted by the Lupus Research Alliance (LRA). However, it is important to note that 24% […] READ MORE
December 14, 2020 In a recent study published in the Journal of Immunology, LRA-funded researcher Dr. John Zhang at Medical University of South Carolina found that a protein called Fli-1 causes immune cells to produce a molecule that causes inflammation. When Fli-1 was hindered by the chemotherapeutic drug camptothecin, immune cells produced fewer inflammatory molecules. […] READ MORE
1 in 2 Lupus Nephritis Patients Don’t Know They Have Lupus New York, NY– December 7, 2020. Significant gaps in education and communication among patients and physicians pose barriers to lupus nephritis (LN) care, according to results of two companion surveys conducted by the National Kidney Foundation (NKF) and the Lupus Research Alliance (LRA). Half […] READ MORE
NEW YORK, NY. December 3, 2020 – The Lupus Research Alliance is proud to announce the 2020 recipients of its Lupus Mechanisms and Targets Award (LMTA). The highly competitive grant gives researchers up to $200,000 a year for up to three years. As indicated by the title of the award, the 2020 awardees are each […] READ MORE
